Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways

Global Journal of Cancer Therapy
Research Article
Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor Receptor (PDGFR) a, KIT, and RET. 
http://www.peertechz.com/Cancer-Therapy/pdf/GJCT-2-109.pdf

Comments

Popular posts from this blog

Peertechz is not Predatory Open Access Publisher

The prevention and cure research of emergency intervention therapy of balloon occlusion of LAD occurring reperfusion arrhythmia

Case Report: Reynolds Syndrome